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Technological and scientiﬁc advances, stemming in large part from the Human Genome and HapMap projects, have made large-scale,
genome-wide investigations feasible and cost effective. These advances have the potential to dramatically impact drug discovery and
development by identifying genetic factors that contribute to variation in disease risk as well as drug pharmacokinetics, treatment
efﬁcacy, and adverse drug reactions. In spite of the technological advancements, successful application in biomedical research would
be limited without access to suitable sample collections. To facilitate exploratory genetics research, we have assembled a DNA resource
from a large number of subjects participating in multiple studies throughout the world. This growing resource was initially genotyped
with a commercially available genome-wide 500,000 single-nucleotide polymorphism panel. This project includes nearly 6,000 subjects
of African-American, East Asian, South Asian,Mexican, and European origin. Seven informative axes of variation identiﬁed via principal-
component analysis (PCA) of these data conﬁrm the overall integrity of the data and highlight important features of the genetic struc-
ture of diverse populations. The potential value of such extensively genotyped collections is illustrated by selection of genetically
matched population controls in a genome-wide analysis of abacavir-associated hypersensitivity reaction. We ﬁnd that matching based
on country of origin, identity-by-state distance, and multidimensional PCA do similarly well to control the type I error rate. The geno-
type and demographic data from this reference sample are freely available through the NCBI database of Genotypes and Phenotypes
(dbGaP).Introduction
Our capacity to measure human genetic variation and ap-
ply it to address scientiﬁc questions related to evolution,1
population structure,2,3 and interindividual phenotypic
variation4 is expanding at an increasing rate. At least as im-
portant as the technologies to measure genetic variation is
the availability of suitable samples and their descriptive
data. In the past, the resources to conduct large-scale ge-
netic investigations have been restricted to a relatively
small number of well-funded academic and commercial
groups, limiting the access to the raw data. However,
recent changes in attitudes in the scientiﬁc community,
on ethical review boards, and at funding agencies are lead-
ing to greater openness in sharing genetic data with the
intent to improve opportunities for discovery through
their creative use and careful integration.5,6
In 2005, GlaxoSmithKline initiated the Population Ref-
erence Sample (POPRES) project with the goal of bringing
together a DNA sample set that would be extensively gen-
otyped in order to support a variety of efforts related to
pharmacogenetics research. We found that the applicationof pharmacogenetics research associated with drug devel-
opment could be hampered by (1) lack of readily available
population controls for adequately powered study designs,
(2) high costs of conducting highly exploratory genome-
wide studies, (3) extended study timelines that may not
meet clinical development needs, and (4) lack of samples
representative of the multinational patient populations
from which the prevalence of pharmacogenetically rele-
vant polymorphisms can be estimated. The POPRES pro-
ject was carried out to begin addressing these issues, with
the further objective of making the resulting genotypic
and demographic data publicly available to help drive
development in the broader genetics research community.
There are many projects, especially in pharmacoge-
netics, wherein the sample collection is focused on the
acquisition of cases. One important example is the identi-
ﬁcation and collection of cases with adverse drug reactions
(ADRs) through postmarketing surveillance. In these situa-
tions, the acquisition or selection of a suitable set of
controls can add a substantial burden to the experimental
process. Having a large collection of DNA samples previ-
ously scrutinized and genetically characterized would1GlaxoSmithKline, Research Triangle Park, NC 27709, USA; 2Department of Biological Statistics and Computational Biology, Cornell University, Ithaca, NY
14853, USA; 3Department of Ecology and Evolutionary Biology, Interdepartmental Program in Bioinformatics, University of California, Los Angeles, CA
90095, USA; 4Department of Human Genetics, University of Chicago, Chicago, IL 60637, USA; 5GlaxoSmithKline, King of Prussia, PA 19406, USA; 6Depart-
ment of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne 1011, Switzerland; 7Department of Neurology, University of California, San
Francisco, CA 94143, USA; 8GlaxoSmithKline, HarlowCM19 5AW,UK; 9National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK;
10Department of Epidemiology and Public Health, Imperial College London, London W2 1PG, UK
*Correspondence: matthew.r.nelson@gsk.com
DOI 10.1016/j.ajhg.2008.08.005. ª2008 by The American Society of Human Genetics. All rights reserved.
The American Journal of Human Genetics 83, 347–358, September 12, 2008 347
facilitate the search for genetic risk factors. This is particu-
larly true if the case samples to be matched with controls
are not of northern European origin, which is the back-
ground of most genome-wide studies published to date
and publicly available. The availability of key demo-
graphic, phenotypic, and clinical data for the selected
subjects would enhance their application.
Investigations into genetic risk factors underlying ADRs
are highly exploratory, because there is generally little a
priori evidence to support a genetic hypothesis. The avail-
ability of population controls with existing genotype data
that could be matched to the cases substantially lowers the
cost and time to conduct this research and could facilitate
exploratory efforts. For ADRs that have relatively low fre-
quency, there is little power lost in the use of population
controls versus drug-treated, clinically matched controls.7
A large resource of genotyped controls would also allow
for more careful matching of what can be genetically
diverse cases to controls on the basis of their patterns of
genetic variation.8
Many pharmacogenetic studies utilize samples collected
in clinical trials, which are becoming increasingly global
and diverse in their origin.9 Therefore, in addition to the
value of genome-wide genotype data for exploratory scans,
the availability of DNA for the subjects included in the
POPRES initiative allows for measurement of variants
that are of particular interest to pharmacogenetic research,
as well as estimation of their population-speciﬁc relative
frequencies. This can be useful for predicting population-
speciﬁc ADR risks or possible variability in drug response.
Furthermore, population genetic studies of more diverse
samples, such as POPRES, provide important information
about the similarity or differentiation of these popula-
tions,10 informing future study designs and interpretation.
The availability of a densely genotyped population refer-
ence sample will increase opportunities for many areas of
genetics research, by us and others, by providing a well-
characterized, readily available set of samples representa-
tive of the populations of interest from which to draw
controls and estimate population parameters of interest.
Furthermore, such resources will foster development of
statistical methods and analysis strategies and provide a re-
source for innovative population-genetics research. In this
paper, we describe the collections currently comprising
5,886 POPRES subjects, genotyping and analysis methods
used in preparing the data being provided to the public do-
main, and selected data-analysis results. Lastly, we present
an example application matching controls to a small set of
ADR cases.
Material and Methods
The subjects included in the POPRES initiative are derived from
ten collections. Each collection is brieﬂy described. Where avail-
able, see accompanying references for further collection details.
All subjects included in this study were either collected in an
anonymous fashion or have beenmultiply coded by the collecting348 The American Journal of Human Genetics 83, 347–358, Septeminstitution as well as the POPRES data managers (see 11 for
deﬁnitions).
UCSF African Americans
African American subjects were recruited across the United States
to serve as controls for studies of multiple sclerosis (MS) genetic
susceptibility conducted at the University of California, San Fran-
cisco.12 In general, individuals were invited to participate in the
study by the probands and constitute primarily spouses or friends
of MS patients. In addition to the ability to give consent and
willingness to participate, inclusion criteria included male and
female gender, age of more than 16 years, no personal or familial
history of MS, and no history of autoimmunity. Exclusion criteria
included chronic diseases and recreational drug use. All study par-
ticipants were self-reported African Americans, but European
ancestry was documented on the basis of genotyping results of
186 informative single-nucleotide polymorphisms (SNPs).13
Healthy Japanese Controls
Participants were recruited through the James Lance GlaxoS-
mithKline Medicines Research Unit in Sydney, Australia. Eligibil-
ity criteria included self-described Japanese ethnic background,
age of more than 20 years, and freedom from chronic disease.
Blood samples were collected in an anonymous fashion, i.e., no
identiﬁers were associated with the biological sample that could
associate it back with the participant. Sex is the only personal
information recorded for each subject.
Healthy Taiwanese Controls
Participants were recruited through the Tri-Service General Hospi-
tal in Taipei, Taiwan. Eligibility criteria included self-described eth-
nicity as Han Chinese, age of at least 20 years, and freedom from
chronic disease. Blood samples were collected in an anonymous
fashion. Sex is the only personal information recorded for each
subject.
Healthy Mexican Controls
Participants were recruited through a hospital-based clinic in Gua-
dalajara, Mexico. Eligibility criteria included self-described ethnic-
ity as Mexican or Hispanic, age of at least 18 years, and freedom
from chronic disease. Blood samples were collected in an anony-
mous fashion. Sex is the only personal information recorded for
each subject.
Healthy Caucasian Controls
Participants were recruited through (1) the Royal Adelaide Hospi-
tal in Adelaide, Australia; (2) Duke University, North Carolina,
USA; and (3) the University of Ottawa Heart Institute, Ottawa,
Canada. Inclusion criteria included self-described ethnicity as
Caucasian, age of at least 18 years, and healthiness. Here, healthy
individuals are those who are free from clinical cardiac, pulmo-
nary, gastrointestinal, hepatic, renal, hematological, neurological,
and psychiatric disease as determined by history, physical exami-
nation, or screening investigations. Blood samples were collected
in an anonymous fashion. Sex is the only personal information
recorded for each subject.
London Life Sciences Population Study
The LOLIPOP study is a population-based study of Indian Asians
and European whites, aged 35–75 years, identiﬁed from the lists
of 58 general practitioners in West London.14 To date, 938ber 12, 2008
Table 1. Summary of the Collections Included in the POPRES Study



















Collection Type Healthy Healthy Healthy Population Healthy Healthy Healthy Healthy Population Population Healthy
Sample Size 436 106 174 431 205 27 105 69 938 2809 586
500K, Initial QC 346 73 109 360 149 27 105 69 598 2509 490
500K, Final QC 346 73 108 359 112 27 105 69 481 2507 -
Genotyping batcha 9 1 1 7 1 2 2 2 3, 7 4, 5, 6 8
Age (min/med/max) 18/45/81 >20 R20 35/50/74 R18 R18 R18 R18 23/54/75 35/52/75 18/22/79
Sex (F:M) 279:157 62:44 84:90 121:310 93:112 18:9 63:42 47:22 213:724b 1508:1301 331:255
500K, Initial QC 223:123 44:29 48:61 103:257 69:80 18:9 63:42 47:22 184:414 1350:1159 285:205
500K, Final QC 223:123 44:29 47:61 103:256 46:66 18:9 63:42 47:22 180:301 1348:1159 -
Call Rate (per SNP)
Median 0.99 0.99 0.98 0.99 0.98 1.00 0.98 0.99 0.99 0.99 -
95th %ile 0.94 0.85 0.87 0.91 0.87 0.85 0.89 0.87 0.92 0.93 -
a Batch defined by month that genotyping completed: 1, Nov. 2005; 2, Mar. 2006; 3, Aug. 2006; 4, Sep. 2006; 5, Nov. 2006; 6, Dec. 2006; 7, Jan. 2007; 8,
Mar. 2007; and 9, May 2007.
b One subject was missing sex information and failed genotyping (i.e., sex could not be inferred).northern Europeans and 431 Indian Asians from this collection
are included in POPRES. Although extensive cardiovascular-
related phenotypic data were collected on these participants, the
POPRES database only includes nonidentifying demographic in-
formation: age at collection, self-identiﬁed race and/or ethnicity,
and country of birth.
CoLaus Study, Lausanne, Switzerland
This is a population-based study of European subjects drawn from
Lausanne, Switzerland, through the Centre Hospitalier Universi-
taire Vaudois (CHUV) University Hospital.15 From this collection,
2,809 subjects were included in POPRES. Although extensive phe-
notypic data were collected on these participants, the POPRES da-
tabase only includes nonidentifying demographic information:
age at collection, self-identiﬁed race and/or ethnicity, native lan-
guage, country of birth, and parental and grandparental countries
of birth.
Duke Healthy Volunteers
Healthy volunteers were recruited from the Duke and North Caro-
lina State University campuses. Volunteers were to be aged be-
tween 18 and 90 years and have no known cognitive impairments.
All races and ethnicities were included. Five hundred and eighty-
six subjects from this collection were included in POPRES. Only
nonidentifying personal demographic information was made
available, including and limited to age at collection, self-identiﬁed
race and/or ethnicity, and sex.
Informed Consent and Ethical Approval
All participants in the component studies that contributed to
POPRES provided written informed consent for the use of their
DNA in genetic studies. The informed-consent form was different
for each study, some providing more explicit descriptions of the
variety of ways that genotype data derived from the sample may
be used than others. Informed consents are available through
the dbGaP submission. The informed consents of the Healthy
Caucasian Controls collections were the most extensive. GivenThe Americanthe anonymized nature of the collection, these samples were
included in POPRES without need for further ethical review. Spe-
ciﬁc ethical review board approval for the controlled release of
deidentiﬁed genotype data was sought for the Healthy Taiwanese
Controls, Healthy Japanese Controls, Healthy Mexican Controls,
CoLaus, and Duke collections. All were granted, with the excep-
tion of the Healthy Taiwanese Controls, which will not be publicly
released. The nature of the original consent and ethical review
board approval for the LOLIPOP collection was sufﬁcient for the
current usage.
Genotyping
Genotyping was performed on the Affymetrix (Mountain View,
CA) GeneChip 500K Array Set with the published protocol for
96-well-plate format. Samples were genotyped in nine batches
over a period of 19 months (Table 1) with a 2%–3% sample dupli-
cate rate to help assess genotype data quality. The CoLaus and
LOLIPOP collections were genotyped in multiple batches. All
other collections were typed within a single batch. Batch informa-
tion for each subject is available with the genotype data.
The dynamic model (DM) genotype-calling algorithm uses
perfect-match and mismatch probe intensities to call genotypes
for individual arrays. DM was used to measure raw experiment
quality. Individual arrays that failed to achieve a 90% DM call
rate (at p ¼ 0.26) were generally reattempted in genotyping by
rehybridization. Duplicate concordance for the StyI arrays was dis-
tinctly lower than that for the NspI arrays on four plates in batch 7
genotyping of the LOLIPOP collection. The samples on these four
plates were regenotyped on the StyI array with fresh DNA aliquots
and with the Affymetrix protocol performed in its entirety.
A series of identity checks was performed. Samples were re-
moved if reported gender was inconsistent with X-linked geno-
types. Samples with no reported gender were left in the dataset,
and their gender was inferred from the genetic data. In addition
to the 500K genotyping, a subset of 88 SNPs was typed with the
single base chain extension (SBCE) assay16 for all subjects (43 on
NspI, and 45 on StyI). The SBCE genotypes were compared with
those called by DM on the 500K SNP panel. Samples less thanJournal of Human Genetics 83, 347–358, September 12, 2008 349
90% concordant between the SBCE data and the Affymetrix 500K
SNP panel data on a single array were removed from the dataset.
Final genotype calling was performed with the Bayesian robust
linear model with Mahalanobis distance classiﬁer algorithm
(BRLMM). Only arrays passing an 85% DM call-rate threshold
were input into BRLMM. BRLMM is a clustering algorithm that
requires batches of arrays to make calls. Arrays were batched
together for BRLMM by plate, with a minimum batch size of ﬁfty.
Affymetrix Power Tools v1.4 was used to run BRLMM, with the
maximum conﬁdence threshold set to 0.3. Defaults were used
for all other parameters. Any inconsistent genotypes for dupli-
cated samples were removed. Samples were considered success-
fully genotyped if they passed identity checks and achieved a
minimum 95% BRLMM call rate on both arrays after removal of
inconsistent genotypes.
There are 500,566 unique markers included in the genotyping
array. A set of 3,247markers identiﬁed asmapping tomultiple sites
on the genome were excluded, leaving 497,625 for subsequent
analysis.
Quality Control
Genome-wide genotyping with an Affymetrix 500K SNP panel was
attempted for all subjects over an 18 month period of time. Two
rounds of initial quality control were performed. The ﬁrst included
standard checks. Only subjects with call rates greater than 95% for
both NspI and StyI chips and conﬁrmed genotype-sex concor-
dance were retained. Relatedness among subjects was evaluated
on the basis of identity-by-descent estimates. This identiﬁed 48
closely related subjects, primarily from the Mexican cohort, that
were subsequently excluded. For the LOLIPOP collection, it was
determined after genotyping that some subjects received for the
POPRES initiative were not a random sample of the larger
LOLIPOP collection. Rather, it consisted of subjects that had
been collected early in the project, which had an initial focus on
recruiting cardiovascular-disease-related patients. A subset of sub-
jects were subsequently selected for inclusion in POPRES with
a 6% coronary heart disease (CHD) rate that brought CHD-related
endpoints in the dataset in line with LOLIPOP overall. This re-
sulted in the removal of 125 subjects. Preliminary principal-com-
ponent analysis (PCA, see below) within Europeans identiﬁed 111
subjects from the European LOLIPOP sample on two genotyping
plates strongly correlated with scores on the second component,
suggesting a problem with genotype data quality. These subjects
were excluded. Two additional subjects were excluded because
they had highly negative inbreeding F scores, which were calcu-
lated with PLINK.17 The F scores were twice the magnitude of all
other samples, indicating potential contamination. A total of
4,835 subjects (82%) passed this ﬁrst round of checks. The second
round of quality control included further PCA to identify subjects
with data quality concerns or misreported genetic ancestry. Four
thousand, one hundred, and eighty-seven subjects (72%) passed
the second round of checks. We note that the Duke data were
not available during these further quality-control measures and
are not included in subsequent analyses. However, the collection
is described herein and the genotype data are publicly available.
With the set of subjects that passed both initial rounds of quality
control, we carried out a series of more stringent quality-control
steps in an effort to further reduce the likelihood of genotyping
errors that could negatively inﬂuence genetic studies using these
data. First, to overcome concerns that the small batch sizes used
to cluster and call genotypes in the original data set could bias350 The American Journal of Human Genetics 83, 347–358, Septembthe results (e.g., 4), a high-performance computing system was
used to apply BRLMM to the entire set of ﬁles, including data
from sample duplicates, for the NspI and StyI chips separately.
We refer to the genotypes generated by this combined calling strat-
egy as ‘‘pooled’’ genotypes and those produced in small groups of
samples as ‘‘batched’’ genotypes. The quality of the pooled versus
batched genotype calls were assessed by comparison of the sample
duplicate concordance and call rates of each (Figure S1 available
online). We found that with the BRLMM quality threshold of
0.3, the batched genotypes resulted in higher duplicate concor-
dance than the pooled calls (99.66% versus 99.56%) as well as
higher call rates (97.66% versus 95.12%). For this reason, we relied
on the batched calls for all reported analyses.
We then evaluated the inﬂuence of the BRLMM quality thresh-
old on duplicate concordance and its relationship to genotype call
rate (Figure S1). As expected, duplicate concordance increased and
call rate decreased as the quality threshold decreased from 0.5
toward zero. On the basis of the improvement in heterozygote
concordance we observed (0.98 to 0.99) by decreasing the quality
threshold from the initial value of 0.3 to 0.2 with only a modest
corresponding decrease in call rates (0.96 to 0.93), we selected
the 0.2 threshold for this more restricted data set.
We then excluded 54,191 SNPs (10.8%) that had three or more
discrepancies between the batched and pooled calls or that
exhibited a batch call rate below 90% (Table S1). These pruned
SNPs showed lower average duplicate-chip concordance rates
(96.6% versus 99.8%) and higher levels of Hardy-Weinberg dis-
equilibrium (20% versus 5% of SNPs with heterozygosity levels
above the p < 0.001 threshold). The remaining SNPs have an
average call rate of 97.7%, and an analysis of individuals for which
duplicate chips were run shows a concordance rate of 99.8%. Our
selection of a 90% threshold contrasts with the 95% call rate
applied in most other studies using the Affymetrix 500K panel.
However, because we use a more stringent conﬁdence threshold
(0.2 versus the BRLMM default value of 0.5), we achieve higher
genotype quality (duplicate concordance) with lower call rates
(see Figure S1).
Principal-Component Analysis
Principal-component analysis was conducted with the smartpca
software18 and default settings with no outlier removal. Analysis
was carried out after the removal of some apparently related indi-
viduals (high identity-by-descent estimates), and individuals were
identiﬁed as outliers in preliminary PCA runs based on regional
subsets of the data (e.g., Europe, East Asia, etc). Furthermore, be-
cause of the large overrepresentation of UK and Swiss individuals,
we randomly selected a subset of 200 UK and 125 French-speaking
Swiss subjects. This resulted in a sample of 3,082 POPRES subjects.
As a reference, and to provide data from Africans in the analysis,
we included genotype data (release 23) on the same subset of
SNPs from 207 unrelated subjects from the four core HapMap sam-
ples19: Yorubans from Ibadan, Nigeria; Japanese from the Tokyo
area; Chinese from Beijing; and Centre d’Etude du Polymorphism
Humain (CEPH) Europeans from Utah (CEU). To reduce the
linkage disequilibrium between markers, we ﬁrst used the PLINK
software to remove all markers with genotypic r2 greater than
0.8, calculated in sliding windows 50 SNPs wide, shifted and recal-
culated every ﬁve SNPs. This process reduced the number of SNPs
analyzed to 286,930.
Previous studies have shown that regions with structural varia-
tion such as inversions can strongly inﬂuence PCA results.4,20er 12, 2008
We found from previous work (data not shown) that plots show-
ing the per-SNP correlation between individual genotype scores
(0, 1, or 2) and individual PC coordinates are a useful diagnostic
for identifying PCs that might be inﬂuenced by long-range LD
regions. For instance, in the initial analysis of European samples,21
known inversions on chromosomes 8p23 and 17q21 appear as
peaks in the correlation plots for some of the lower PCs (e.g., PC 3).
(Alternatively, we could have plotted the absolute values or the
square of SNP loadings from the PCA, but here we used the corre-
lation-based approach because much of this work was done before
the release of recent versions of smartpca that provide the SNP
loadings.) The only strong peaks in the correlation plots within
the top seven PCs were for the approximately north-to-south Eu-
ropean principal component, which exhibited two large peaks,
with p values of association as extreme as 1040 to 10100. One
of these peaks located at 134.6–137.6 Mb on chromosome 2
centered on the LCT gene (136.4–136.5 Mb). The other peak on
chromosome 6 at 29.1–32.8Mb contained themajor histocompat-
ibility complex (MHC) complex, including the HLA-A, -B, -C, -DR,
and -DQ genes.
To assess whether such aberrant regions might inﬂuence the
PCA results and obscure genome-wide patterns, we performed
a second PCA analysis where we ﬁrst removed SNPs from regions
surrounding putative peaks of correlation. Although none of the
other ﬁrst seven PCs, aside from PC 5, showed a strong peak of
correlated markers, we conservatively removed all SNPs within
2 Mb of a marker highly correlated with any of the ﬁrst ten prin-
cipal components. We deﬁned the threshold for calling highly
correlated SNPs as being within the top 0.2% of r2 values for corre-
lations of markers against the given principal component. This
process excluded over half of the markers (including the lactase
and MHC regions mentioned above), leaving 226,211 SNPs for
the subsequent analysis, and resulted in a ﬁnal set of 143,893
SNPs after excluding markers by the procedure based on the slid-
ing-window-based pruning step described above. Using this
more stringent set of SNPs, we reran PCA on the same set of indi-
viduals and found that, aside from negation of the eigenvectors,
the PCs revealed the same structure as when the full set of markers
was used, and the ﬁrst seven principal components had a correla-
tion greater than 0.98 between the two runs. This suggests that the
initial PCA was capturing genome-wide patterns of variation
rather than patterns localized to speciﬁc sets of markers, and the
peaks of correlation observed were simply particular sets of
markers that happened to be correlated with the population struc-
ture (such as in the case of the lactase gene with PC 5, the roughly
north-to-south European PC). Although the results were similar
between the two runs, we present the results from the second of
the two PCA runs.
Case-Control Matching and Genome-wide Analysis
We performed four different methods of case-control matching to
assess their impact on type I error rates in an example motivated
by the search for major genetic risk factors for adverse drug reac-
tions. Twenty-two HIV-positive patients of European origin with
clinically diagnosed abacavir-associated hypersensitivity reaction
were genotyped with the Affymetrix 500K SNP panel as previously
described.7 One case was dropped because of very low genotyping
efﬁciency (<85%). Ten controls were matched to each case by four
methods: (1) continental origin, selecting Europeans from the
United Kingdom, (2) country of sampling or country of birth
(if available), (3) minimizing pairwise identity by state (IBS)The Americandistance, and (4) minimizing pairwise distance among selected
principal components.
Continent of origin matching was carried out with POPRES sub-
jects of self-identiﬁed European origin who were collected in, or
reported to have ancestry from, England or the United Kingdom.
Country matching was carried out by selection of sex-matched
controls from the same country of origin as the cases (Table S2).
When there were excess numbers of controls available, ten were
randomly selected for each case. Controls from adjoining coun-
tries were selected when there were insufﬁcient numbers of con-
trols available from the case countries. IBS matching was carried
out by estimation of the pairwise IBS distance from each case to
each POPRES subject that satisﬁed the quality-control criteria
described above. IBS estimation was carried out with PLINK
v1.01,17 excluding 58,089 SNPs found within genomic regions
highly correlated with the scores from the top four PCs in a Euro-
pean-only analysis (as described above), 61,275 SNPs missing
more than 5% of genotypes, and 96,880 SNPs with minor-allele
frequencies less than 5%. For each case, the ten POPRES subjects
with the shortest IBS distance to the case were selected as controls.
PCA matching was carried out with PCA scores. PCA, excluding
58,089 SNPs described above, was carried out on the combined
cases and subset of POPRES deﬁned as European origin, with anal-
ysis limited to 200 subjects per country and principal-component
scores assigned to all eligible controls. Inspection of the resulting
eigenvalues led to the selection of the ﬁrst four components for
genetic matching. Prior to matching, eigenscores were rescaled
to reﬂect their relative importance bymultiplication of each eigen-
score by the square root of the corresponding eigenvalue. Pairwise
Euclidean distances were then estimated between each case and all
POPRES subjects. Ten controls were selected for each case; they
were randomly selected controls within the 2.5th percentile of
the multivariate distance distribution, with care not to allow the
reuse of controls among cases.
For each of the four selections of controls, genome-wide associ-
ation analysis was carried out with Fisher’s exact test, as described
previously.7 SNPs were excluded from analysis if they weremissing
mapping position, had genotyping efﬁciency less than 90%, had
minor-allele frequency less than 1%, or had deviations of geno-
type frequencies from Hardy-Weinberg expectations that were
highly signiﬁcant (p value < 107) in controls. We also excluded
26 SNPs identiﬁed in a previous study to have highly erroneous
genotype calls within the 21 cases.7 Comparisons across analyses
were carried out on a ﬁnal set of 393,699 SNPs that passed the
QC in all four case-control samples.
Public Data Availability
The subject-level data described in this study are available via the
dbGaP archive sponsored by the National Center for Biotechnol-
ogy Information (see Web Resources) pending acceptance of a
standard Data Use Certiﬁcation and endorsement by the request-
ing investigator’s institution. Data include the demographic vari-
ables listed in the following section, PCA scores, and genotype
data described herein.
Results
Sample and Data Overview
The POPRES study includes DNA samples from 5,886 sub-
jects derived from ten constituent collections (Table 1; theJournal of Human Genetics 83, 347–358, September 12, 2008 351
Figure 1. Distribution of Minor-Allele Frequency by Collection
Colors and line types for the densities of each collection are shown within the figure.LOLIPOP study is divided between subjects of Indian Asian
and European origin). Based on the inclusion criteria and
recruiting methods, these collections are broadly described
as either population samples or healthy subjects (see
Methods for collection-speciﬁc details). Basic demographic
data available for all subjects includes sex, country of col-
lection, and self-described racial background. Additional
information available for some collections includes age at
collection, state or city of collection, country of birth,
parental country birthplaces, grandparental country birth-
places, and native language. Complete demographic sum-
maries of each collection are provided in the Supplemental
Results and subject-level details are available via controlled
access in a public repository (seeWeb Resources). All partic-
ipants were at least 18 years of age at time of recruitment.
The sex ratio varies widely among studies.
The distribution of minor-allele frequencies by collec-
tion is presented in Figure 1. The frequency distributions
are very consistent among the ﬁve European collections
as well as between the two East Asian collections. However,
the distributions differ substantially among the ﬁve major
geographic regions represented by these collections. East
Asia shows the highest proportion of low frequency SNPs
(22% of SNPs less than 0.01 frequency), followed by
Europe (15%), South Asia (13%), Mexico (10%), and lastly
African American (1.9%). These frequency distributions
differ markedly from those observed in the resequenced
ENCODE regions of the HapMap project,19 wherein Euro-
peans showed an increase in low frequency SNPs com-
pared to East Asians and levels comparable to Africans.
These differences reﬂect the biased nature of the SNPs
included on the genotyping array.22352 The American Journal of Human Genetics 83, 347–358, SeptemThe distribution within African Americans is most dis-
tinct. There is a large proportion of SNPs with frequencies
between 0.05 and 0.2, which is consistent with the African
HapMap ENCODE and Affymetrix 500K SNP data (Fig-
ure S2). However, the African Americans have a very small
proportion of low frequency andmonomorphic SNPs com-
pared to the other continental groups and compared to
HapMap Africans (Figure S2). This does not reﬂect the
underlying SNP frequency distribution in African Ameri-
cans,1 but rather the inﬂuence of African and European
admixture of African Americans with the SNPs in this
panel. Although 15% of these SNPs have minor-allele fre-
quencies less than 0.01 in Europeans and 11% in YRI,
only 1.6% of them have minor-allele frequencies less
than 0.01 in both. This smaller proportion of low fre-
quency SNPs suggests that this panel would be more infor-
mative for studies in African Americans, compared to
Africans.
Analysis of Population Structure
We performed a principal-component analysis on the
genotype data to investigate the main axes of variation
present in this sample. PCA makes inferences solely on
the basis of the genotype data without inclusion of any
other information; hence, the analysis results reﬂect the
clustering within those data. The results of the PCA with
the POPRES and HapMap data combined exhibit the antic-
ipated structure ﬁrst of clustering continents and next of
regions within continents (Figure 2 and Figures S3 and
S4). As expected, the ﬁrst principal component (PC 1) dis-
tinguishes Africans from non-Africans. The next three
principal components also characterize continentalber 12, 2008
Figure 2. Genetic Structure Illustrated through Scatter Plots of Consecutive Principal Components
Subject scores are colored by continental and/or ethnic origin (see legend). East Asian populations are indicated by varying point types.
Percent of variation explained by each component is given in parentheses on each axis label.regions: PC 2 distinguishes East Asians from Africans and
Europeans, with South Asians and Mexicans at intermedi-
ate values; PC 3 distinguishes South Asians from East
Asians; and PC 4 distinguishes Mexicans from non-
Mexicans.
The subsequent principal components mark within-con-
tinent variation. PC 5 reveals a north-to-south cline within
Europeans (Figure 3), consistent with existing studies of
European substructure.20,23,24 The majority of Europeans
sampled from North America and Australia are most simi-
lar to northern Europeans, with modest numbers of outlier
observations. The CEU sample had the highest median
scores on this component, followed by Australia and USA
(collected in North Carolina), then by Canada, having
a median more similar to central than to northern Europe.The AmericanPC 6 distinguishes the African Americans from the
HapMap Africans. Interpretation of the asymmetrical dis-
tributions of the Africans and African Americans along
the European north-south cline in Figure 2C suggests
that the Africans are slightly more similar to southern
Europeans, whereas the African Americans lie slightly
shifted to the right and on average appear more like north-
ern Europeans on this principal component. This may be
partially due to northern European admixture in African
Americans. However, caution should be used in this inter-
pretation, because the Africans and African Americans are
slightly more similar to their respective subpopulations of
Europeans only on genotypes that distinguish southern
from northern Europeans, and this similarity is not
necessarily true of overall genotype relatedness.Journal of Human Genetics 83, 347–358, September 12, 2008 353
Figure 3. Distribution of Subject-Level Principal Component 5 Scores by Reported Ancestry
Each box and whisker indicates the median (heavy line), interquartile range (IQR, box), and minimum and maximum observations (whis-
kers). Whiskers are truncated at the last observation within 1.5 times the IQR from the edge of the box, with outliers shown individually.
Plots for the remaining principal components are available in Figure S2, available online.Principal component 7 (Figure 2D) separates the three
East Asian populations: Japan (left), HapMap CHB (center
right), and Taiwan (far right). Note that the Africans, un-
like African Americans or other continents, appear more
similar to the Chinese than Japanese on the PC that
distinguishes East Asian substructure. We do not show
further results because PC 8 and subsequent PCs display
substructure within Africans and African Americans, but
do not correspond to any known geographic or popula-
tion structure among individuals. The ﬁrst two PCs ex-
plain a total of 9.2% of the genetic variation within this
sample. The remaining ﬁve PCs, though clearly informa-
tive, only explain an additional 1.0% combined. Loadings
for the ﬁrst seven PCs are included in Table S3. HapMap
subject scores are available in Table S4, and POPRES sub-354 The American Journal of Human Genetics 83, 347–358, Septemject scores are available with the subject-speciﬁc data
through dbGaP.
Case-Control Matching
One of the primary motives in the development of the
POPRES resource was to provide a source of pregenotyped
population samples that could be drawn on as needed as
a comparator (i.e., control) group for association studies
of adverse drug reactions. The rationale for this approach
and its implications on statistical power for ADR genetics
research have been considered elsewhere.7 In that previous
work, we argued that use of population controls required
that they be matched appropriately to the cases. Given
such a resource, there are multiple ways in which cases
and controls could be matched. Here, we extend ourber 12, 2008
Figure 4. P-Plot Comparing Observed versus Expected Proportion of Associations over a Range of Significance Thresholds
Separate lines are presented for each of the four control matching strategies. Results of the allelic exact test are shown on the left and
genotypic exact tests on the right. A light gray line corresponds to unity.previous work with 21 clinically diagnosed abacavir-associ-
ated hypersensitivity reaction (ABC HSR) cases7 by com-
paring four strategies for matching them to these POPRES
controls: (1) matched by continental origin by selecting
northern Europeans from the United Kingdom, (2)
matched by reported country or region of birth, (3) mini-
mizing pairwise identity-by-state (IBS) distances between
cases and controls (Figure S5), and (4) minimizing
distances between cases and controls on the basis of multi-
variate PCA scores (Figures S6 and S7). For each method,
controls were matched to this small sample of cases in
a 10:1 ratio.
The results of each genome-wide association analysis,
using controls selected as described above, are summarized
in Figure S8. All four methods identify the knownMHC re-
gion (tagging HLA-B*5701) among the top 20 associated
SNPs, with PCA matching yielding the lowest p value
and highest rank (p value¼ 2.13 106, rank¼ 2), followed
by UK (4.2 3 106, 8), country (7.6 3 106, 5), and IBS
(2.9 3 105, 16) matching. A comparison of the ranking
among the top 100 SNPs from each analysis showed that
the country- and IBS-matchingmethodswere themost con-
cordant (r ¼ 0.58). Country- and PCA-matching methods
were the least concordant (r ¼ 0.03). The remaining pair-
wise comparisons were onlymodestly correlated (r< 0.15).
With a single realization of each matching algorithm, it
is not possible to assess the impact of the matching on the
power to identify the known effect of the HLA-B*5701
allele. However, with nearly 400,000 SNPs for which the
null hypothesis of no association is true, we can reasonably
assess the effect of each matching algorithm on the type I
error rate. The proportion of tests with p values falling
below a range of signiﬁcance thresholds, shown in Figure 4,The Americanis very similar among the country (genomic control l ¼
1.00 for allelic test), IBS (l ¼ 1.00), and PCA (l ¼ 1.00)
matching methods and falls close to the expected propor-
tion at each level. In contrast, the analysis that only drew
from population controls in the UK (l ¼ 1.13) resulted in
a signiﬁcant excess of low p values at all levels below 0.1,
roughly doubling the numbers observed with the other
matching methods. Whereas all four control matching
procedures resulted in relatively low p values for the
known association, the UK controls (i.e., matching only
by continent) suffered from an increase in the false-posi-
tive rate, even with this small number of cases. Figure S8
shows that relatively small p values are observed across
the genome and vary substantially across control
selections.
Discussion
We have brought together DNA from nearly 6,000 subjects
participating in ten studies with ancestry from ﬁve major
geographic regions and dozens of countries as a resource
for genetics research. Genotype data from a genome-wide
panel of 500,000 SNPs attempted on nearly all participant
samples were carefully evaluated to yield a set of subjects
and markers with high data quality that may be appropri-
ate for a range of applications. These data are freely avail-
able for legitimate research purposes through the public
dbGaP website.
Principal-component analysis of these data illustrates
the overall data quality, in terms of both the genotypes
and the labels of subject origins. The seven highly informa-
tive principal components provided a high degree ofJournal of Human Genetics 83, 347–358, September 12, 2008 355
discrimination among African, East Asian, South Asian,
European, andMexican ancestry. They also illustrated ﬁner
differentiation in the separation of Africans and African
Americans and differentiation between the three Asian
populations of Japan, mainland China, and Taiwan, and
they highlighted genetic gradients within African Ameri-
cans, Mexicans, and Europeans. These results provided
ample opportunities to identify subjects with ancestry
labels that do not match their genetic background. Very
few subjects demonstrated PC score patterns that deviated
noticeably from the majority of their groups. The score
information (available via dbGaP) may be used in future
applications to re-label subjects or to exclude them from
further analyses.
The potential impact of cases and controls that are poorly
matched for their genetic background on the type I error
rates of association studies is well understood (e.g., 25).
Most studies of unrelated subjects attempt to control for
this through careful study design and sampling (e.g., 26),
statistical correction (e.g., 27), or measurement and
correction of sample structure by use of PCA or related
methods (e.g., 28,29). Alternatively, sets of healthy or popu-
lation controls that have been genotyped for compatible
genome-wide panels can be queried for controls that
genetically match the genotyped cases,8,30 recently illus-
trated for genome-wide genotype data.8 In the limited
application presented here with 21 subjects with abacavir-
associated hypersensitivity reaction, we found that match-
ing controls to cases on the basis of country of origin,
minimizing pairwise IBS distances, and minimizing dis-
tances among the top principal components were similarly
effective in controlling type I error. The latter twogenotype-
basedmethods would clearly be preferredwhen there is un-
certainty about genetic background of the cases or controls,
or when the populations sampled are admixed or otherwise
genetically heterogeneous. It is important to note that with
such a small number of cases included in this example ap-
plication, there is insufﬁcient power for subtle population
or genotype-quality-dependent differences between the
cases and controls to be detected. An analysis with a larger
number of cases and controls could highlight limitations
in the sample-matching schemes or in the POPRES data
that were not readily apparent in this example.
Most studies that include whole-genome genotype data
do not have need for external sources of controls for key
analyses, and even with ~5,000 subjects genotyped, the
power of this resource to investigate common disease ge-
netics is limited, particularly for non-European popula-
tions. Nevertheless, the data published herein should
prove useful for characterizing the genetic background of
study participants, particularly for small sample sizes or
poorly characterized sample collections. POPRES genotype
data may be included with study genotype data to conduct
analyses of population structure. The Affymetrix 500K SNP
panel shares a reasonably large number of SNPs with other
popular SNP panels, including Illumina 1M (138,143) and
Affymetrix 6.0 (469,874), which in many cases will be356 The American Journal of Human Genetics 83, 347–358, Septemsufﬁcient for inferring patterns of population structure.
Subject scores may also be computed directly from the
SNP loadings published herein (Table S3). The legitimacy
of this approach is most obvious for genotype data derived
from the Affymetrix 500K and 6.0 SNP panels. However, it
should be possible to derive informative subject scores
with this approach from the subset of SNPs that overlap
with the Illumina panels, though the accuracy of this ap-
proach has not been assessed. Beyond the global patterns
of variation observed in the analyses included in this
report, ﬁner-scale structure may also be investigated in
subsets of the POPRES data, such as within Europeans.21
As described, nearly all of the subjects currently included
in POPRES have been genotyped with the Affymetrix 500K
SNP panel. The choice to standardize on this panel was
largely inﬂuenced by the timing of the project. Since the
time this project was initiated, genome-wide genotyping
panels from multiple vendors have expanded and im-
proved in quality. Although there is no expectation that
the entire POPRES collection will be genotyped on another
genome-wide panel, selected subsets will be genotyped
with newer panels as required to support ongoing research,
and much of these data will eventually be deposited to
dbGaP. This includes existing data on the Illumina (San
Diego, CA) 550K and 1M panels typed on ~500 POPRES
subjects of European origin. Developments around use of
representative patterns of haplotype structure to impute
unmeasured genotypes may also be employed with this
and similar resources to make the results from the Affyme-
trix 500K panel compatible with other panels.31–33
In developing this resource, we considered several alter-
native designs. The ﬁrst objective is to use this collection as
a resource for generating contrast (control) groups for
pharmacogenetic studies. In the context of studying the
occurrence of an ADR, the controls would ideally match
the cases for disease status, treatment, duration of treat-
ment, age, gender, and any other disease- or ADR-related
clinical characteristics so that associated markers can be in-
ferred to be causally related. However, developing a general
resource applicable to a diversity of diseases and relevant to
a number of drugs (approved or in development) would
probably require extremely large samples and be difﬁcult,
if not impossible, to ascertain. When the outcome under
study is relatively rare (prevalence < 10%), as many ADRs
are, an alternative to having treatment-matched patients
is having patients matched for disease status but unknown
for their propensity for an adverse event given the lack of
treatment. Because the outcome is rare, a relatively small
percentage of the controls would have had the adverse
event, if they had been treated. This more feasible design
would result in little loss of power to detect even modest
genetic effects. Even so, unless the number of relevant
diseases is very small and foreseeable, even large collection
sizes will be limited once study-speciﬁc strata are
considered.
With these limitations, we considered that a collection
representative of the populations from which the casesber 12, 2008
were sampled without regard to disease status would be the
most feasible design. A population sample design would
result in disease frequencies in proportions similar to those
of the population at large. For rare outcomes, the fre-
quency of those genetically predisposed to the outcome
of interest would be low, resulting in a small loss of power
to identify predisposing factors. In this design, the disease
status and outcome of interest are likely to be confounded,
requiring further investigation to disentangle the rele-
vance of each result.
It is often of interest to estimate the frequencies of alleles
associated with a pharmacogenetic response. One can
estimate these frequencies in the population of affected
individuals (i.e., patients) or in the population at large.
Although estimates in patients are more representative of
the intent to treat population, having an appropriate sam-
ple for a large number of diseases is not feasible. Estimating
the genetic parameters in the population at large will only
be limiting if the genetic variant, or one in linkage disequi-
librium with it, plays an important role in both the disease
susceptibility and the pharmacogenetic response under
investigation. This may be expected to occur when the var-
iations with pharmacogenetic impact are located within
the drug target. In such cases, caution should be exercised
in the interpretation of results.
The range and value of genetic studies possible with such
a resource rests largely on the quality, quantity, and
sampling of the data available. The public release of the
POPRES resource will have immediate opportunities to
impact a variety of studies and contribute to the growing
body of data that will further many areas of human genet-
ics research. We support the public access to these data for
appropriate research uses and encourage the further devel-
opment of such resources for the beneﬁt of the scientiﬁc
community.
Supplemental Data
Supplemental Data include eight ﬁgures, four tables, and a sum-
mary of demographic variables available for each collection and
can be found with this article online at http://www.ajhg.org/.
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